CN104173301A - 一种前列地尔冻干乳及其制备方法 - Google Patents
一种前列地尔冻干乳及其制备方法 Download PDFInfo
- Publication number
- CN104173301A CN104173301A CN201410440057.3A CN201410440057A CN104173301A CN 104173301 A CN104173301 A CN 104173301A CN 201410440057 A CN201410440057 A CN 201410440057A CN 104173301 A CN104173301 A CN 104173301A
- Authority
- CN
- China
- Prior art keywords
- phosphatidylcholine
- phosphatidylinositols
- alprostadil
- freeze
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229960000711 alprostadil Drugs 0.000 title claims abstract description 47
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title claims abstract description 47
- 238000004108 freeze drying Methods 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 39
- 239000006071 cream Substances 0.000 title abstract 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 26
- 150000003905 phosphatidylinositols Chemical class 0.000 claims abstract description 26
- 239000007924 injection Substances 0.000 claims abstract description 20
- 238000002347 injection Methods 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 229940067626 phosphatidylinositols Drugs 0.000 claims description 37
- 239000003921 oil Substances 0.000 claims description 36
- 235000019198 oils Nutrition 0.000 claims description 36
- 210000000481 breast Anatomy 0.000 claims description 32
- 210000003022 colostrum Anatomy 0.000 claims description 27
- 235000021277 colostrum Nutrition 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 229940090044 injection Drugs 0.000 claims description 19
- -1 mustard acyl phospholipids Chemical class 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 11
- 239000012982 microporous membrane Substances 0.000 claims description 9
- 239000003549 soybean oil Substances 0.000 claims description 9
- 235000012424 soybean oil Nutrition 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000004006 olive oil Substances 0.000 claims description 7
- 235000008390 olive oil Nutrition 0.000 claims description 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 4
- 244000056139 Brassica cretica Species 0.000 claims description 4
- 235000003351 Brassica cretica Nutrition 0.000 claims description 4
- 235000003343 Brassica rupestris Nutrition 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000002148 esters Chemical group 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 235000010460 mustard Nutrition 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 claims description 3
- MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 229940074046 glyceryl laurate Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 238000012859 sterile filling Methods 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 abstract description 4
- 238000005538 encapsulation Methods 0.000 abstract description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 19
- 239000000839 emulsion Substances 0.000 description 19
- 238000001035 drying Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 9
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010792 warming Methods 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
- 229940070940 alprostadil injection Drugs 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008348 synthetic phosphatidyl choline Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Abstract
Description
时间 | 对比实施例1 | 实施例1 |
10天 | 2.9% | 1.6% |
30天 | 7.3% | 4.2% |
总含量(%) | 水相中含量(%) | 包封率(%) | |
对比实施例2 | 116.5 | 12.6 | 89.2 |
实施例2 | 117.3 | 5.1 | 95.7 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410440057.3A CN104173301B (zh) | 2014-08-29 | 2014-08-29 | 一种前列地尔冻干乳及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410440057.3A CN104173301B (zh) | 2014-08-29 | 2014-08-29 | 一种前列地尔冻干乳及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104173301A true CN104173301A (zh) | 2014-12-03 |
CN104173301B CN104173301B (zh) | 2018-08-10 |
Family
ID=51954834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410440057.3A Active CN104173301B (zh) | 2014-08-29 | 2014-08-29 | 一种前列地尔冻干乳及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104173301B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015184981A1 (zh) * | 2014-06-04 | 2015-12-10 | 北京蓝丹医药科技有限公司 | 一种前列地尔组合物及其注射液和冻干制剂 |
CN105748415A (zh) * | 2016-03-18 | 2016-07-13 | 上海方予健康医药科技有限公司 | 一种前列地尔冻干微乳组合物及其制备方法 |
CN106389328A (zh) * | 2015-07-31 | 2017-02-15 | 北京蓝丹医药科技有限公司 | 一种注射用前列地尔脂肪乳 |
CN110045034A (zh) * | 2019-04-30 | 2019-07-23 | 江苏东南纳米材料有限公司 | 一种高效液相色谱测定二芥酰磷脂酰胆碱含量的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536532A (zh) * | 2013-10-25 | 2014-01-29 | 北京蓝丹医药科技有限公司 | 一种前列地尔组合物及其制备方法 |
CN103655487B (zh) * | 2013-11-15 | 2015-05-06 | 西安力邦制药有限公司 | 一种注射用前列地尔冻干乳剂 |
CN105310976B (zh) * | 2014-06-04 | 2018-08-21 | 北京蓝丹医药科技有限公司 | 一种稳定的前列地尔组合物 |
-
2014
- 2014-08-29 CN CN201410440057.3A patent/CN104173301B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015184981A1 (zh) * | 2014-06-04 | 2015-12-10 | 北京蓝丹医药科技有限公司 | 一种前列地尔组合物及其注射液和冻干制剂 |
CN106389328A (zh) * | 2015-07-31 | 2017-02-15 | 北京蓝丹医药科技有限公司 | 一种注射用前列地尔脂肪乳 |
CN106389328B (zh) * | 2015-07-31 | 2019-07-23 | 北京蓝丹医药科技有限公司 | 一种注射用前列地尔脂肪乳 |
CN105748415A (zh) * | 2016-03-18 | 2016-07-13 | 上海方予健康医药科技有限公司 | 一种前列地尔冻干微乳组合物及其制备方法 |
CN105748415B (zh) * | 2016-03-18 | 2019-05-07 | 上海方予健康医药科技有限公司 | 一种前列地尔冻干微乳组合物及其制备方法 |
CN110045034A (zh) * | 2019-04-30 | 2019-07-23 | 江苏东南纳米材料有限公司 | 一种高效液相色谱测定二芥酰磷脂酰胆碱含量的方法 |
CN110045034B (zh) * | 2019-04-30 | 2022-02-08 | 江苏东南纳米材料有限公司 | 一种高效液相色谱测定二芥酰磷脂酰胆碱含量的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104173301B (zh) | 2018-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105012248A (zh) | 一种注射用前列地尔脂肪乳及其制备方法 | |
CN103040748B (zh) | 一种培美曲塞二钠脂质体注射剂 | |
CN102579341A (zh) | 一种多西他赛固体脂质纳米粒及其制备方法 | |
CN104173301A (zh) | 一种前列地尔冻干乳及其制备方法 | |
CN112137958A (zh) | 一种含阿霉素与免疫佐剂组合药物脂质体及其制备方法 | |
WO2010127541A1 (zh) | 长春花生物碱纳米乳剂注射液及其制备方法 | |
CN102755292B (zh) | 一种含有二甲双胍囊泡类给药系统及其应用 | |
CN1980671B (zh) | 含有水难溶性喜树碱的脂质体制剂 | |
CN105919949B (zh) | 一种稳定的氟比洛芬酯冻干乳及其制备方法 | |
CN104688721A (zh) | 一种含紫杉醇脂质体的抗类风湿性关节炎药物凝胶剂及其制备方法 | |
CN105213313A (zh) | 一种地西他滨长循环脂质体冻干制剂及其制备方法 | |
US20180153818A1 (en) | Phospholipid-coated therapeutic agent nanoparticles and related methods | |
TW201705941A (zh) | 經磷脂塗覆的治療劑奈米粒子及其相關方法 | |
CN106389328B (zh) | 一种注射用前列地尔脂肪乳 | |
CN102188379A (zh) | 载药脂质体的制备方法 | |
CN104306334B (zh) | 泰万菌素脂质体及其混悬液和脂质体粉末 | |
CN108721644B (zh) | 一种紫杉烷类药物脂质体制备方法 | |
CN101829054A (zh) | 一种注射用前列地尔亚微乳及制备方法 | |
KR102175069B1 (ko) | 음이온성 약물 전달용 지질 나노입자의 동결건조 조성물 및 방법 | |
CN101732232B (zh) | 一种多烯紫杉醇纳米粒组合物 | |
CN105497871A (zh) | 一种卡非佐米药物的脂质体冻干组合物及其制备方法 | |
CN105748415B (zh) | 一种前列地尔冻干微乳组合物及其制备方法 | |
CN103830182A (zh) | 一种长循环伊立替康脂质体组合物及其制备方法 | |
CN114432245B (zh) | 一种人参皂苷紫杉醇脂质体、其制备方法和应用 | |
CN103040751B (zh) | 一种细辛脑脂质体注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240116 Address after: Room 101, 1st Floor, Building 4, No. 41 Yongda Road, Daxing District, Beijing, 100037 Patentee after: Beijing Changbai Technology Co.,Ltd. Address before: 100044 Beijing Yizhuang economic and Technological Development Zone, Chuang Chuang fourteen Street Jie Jie science park two phase 20, building 15. Patentee before: BEIJING LANDAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240407 Address after: 221000 No.18, Yangshan Road, Xuzhou Economic and Technological Development Zone, Xuzhou City, Jiangsu Province Patentee after: NHWA PHARMA. Corp. Country or region after: China Address before: Room 101, 1st Floor, Building 4, No. 41 Yongda Road, Daxing District, Beijing, 100037 Patentee before: Beijing Changbai Technology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |